Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erick Hernandez

Pediatric Gastroenterology Miami, FL Medical Doctor

NPI 1609803261 CMS profile 299127

1601 Nw 12Th Ave, Box 016960 M851, Miami, FL 33101

Open in the dashboard

General payments

$12,055

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erick Hernandez of Miami, FL is reported in the CMS Open Payments database as having received $12,055 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,037 38
2024 General $766 33
2023 General $1,296 38
2022 General $1,453 27
2021 General $812 30
2020 General $2,334 20
2019 General $4,356 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erick Hernandez
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Erick Hernandez were reported at $1,037. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Erick Hernandez Pediatric Gastroenterology median Middle half National median
2019 $4,356 $131 $41–$311 $163
2020 $2,334 $79 $23–$223 $114
2021 $812 $104 $32–$321 $132
2022 $1,453 $125 $37–$331 $149
2023 $1,296 $169 $55–$440 $160
2024 $766 $196 $73–$563 $164
2025 $1,037 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Retrophin, Inc. $7,232 37 payments
  2. Janssen Biotech, Inc. $731 41 payments
  3. AbbVie, Inc. $701 34 payments
  4. Genzyme Corporation $508 17 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $492 18 payments
  6. Janssen Scientific Affairs, LLC $311 4 payments
  7. Albireo Pharma, Inc. $260 3 payments
  8. Mirum Pharmaceuticals, Inc. $253 6 payments
  9. Ipsen Biopharmaceuticals, Inc $223 9 payments
  10. QOL Medical, LLC $222 15 payments
  11. Other $1,123 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,100 15 payments
  2. Food and Beverage $4,987 195 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $750 1 payment
  4. Education $218 10 payments
Products named General payments · program years 2019–2025
  1. (820) Cholbam $5,784 26 payments
  2. STELARA $817 34 payments
  3. Thiola $750 1 payment
  4. Bylvay $484 12 payments
  5. DUPIXENT $471 15 payments
  6. GATTEX $329 11 payments
  7. HUMIRA $299 15 payments
  8. SKYRIZI $295 13 payments
  9. Livmarli $253 6 payments
  10. TREMFYA $206 10 payments
  11. Other $2,224 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Pediatric Medicine: 38

Drug cost

$6,240

Median for Pediatric Medicine: $2,769

Branded share of claims

0%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Famotidine Generic 13 $6,240

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$53,723

Of which drugs: $51,771

Medicare patients

15

Average age 62

Services billed

16,741

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $158
  • Regeneron Healthcare Solutions, Inc. $72
$229 — —
Bylvay
  • Ipsen Biopharmaceuticals, Inc $124
$124 — —
Sucraid
  • QOL Medical, LLC $75
$75 — —
CUVRIOR
  • ORPHALAN INC $68
$68 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record